Presumably, combining anti-CSF1 treatment with checkpoint blockade such as via anti-PD1 and anti-CTLA4 antibodies may enhance immune cell anti-tumor activity and improved efficacy over single-agent treatment as was demonstrated in established pancreatic ductal adenocarcinoma tumors (57). Here, CSF1 is linked to pancreatic ductal adenocarcinoma.